New hope for HER2+ breast cancer patients who stopped responding to standard therapy
NCT ID NCT07366840
First seen Jan 27, 2026 · Last updated Jun 02, 2026 · Updated 13 times
Summary
This study tests a new drug combination (RC48 plus chemotherapy) against standard treatment (trastuzumab/inetetamab plus chemotherapy) in people with HER2-positive advanced breast cancer whose disease worsened after prior therapy with a topoisomerase I inhibitor antibody-drug conjugate. About 268 participants will be enrolled to see if the new combo improves progression-free survival. The goal is to find a better treatment option for this specific group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.